Sovaldi is expensive, but this drug cost N.C. Medicaid even more
The Gilead Sciences (Nasdaq: GILD) Hepatitis C treatment Sovaldi has contributed to increasing Medicaid costs in recent years, but there was one drug that cost Medicaid even more. The drug that cost N.C. Medicaid more than any other in 2014 was the antipsychotic drug Abilify, a treatment for Major Depressive Disorder, Irritability Associated with Autistic Disorder and other indications, made by Otsuka America Pharmaceutical. In 2014, Ability cost N.C. Medicaid $85 million, according to a report… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 15, 2015 Category: Biotechnology Authors: Jason deBruyn Source Type: news

Abilify (aripiprazole) Digital Medicine for Treatment of Schizophrenia
Abilify (aripiprazole), an orally administered dopamine partial agonist and a seratonin antagonist, was approved by US Food and Drug Administration (FDA) in November 2002 for the treatment of schizophrenia. (Source: Drug Development Technology)
Source: Drug Development Technology - November 23, 2015 Category: Pharmaceuticals Source Type: news

Facts You Should Know if Taking Abilify for...
Read about the use of Abilify in bipolar disorder and other health conditions, as well as information on its side effects and two black box warnings. (Source: About.com Bipolar Disorder)
Source: About.com Bipolar Disorder - November 17, 2015 Category: Psychiatry Authors: bipolar.guide at about.com Tags: health Source Type: news

Kids' Aripiprazole Ingestion May Have Led to False-Positive Amphetamine Results (FREE)
By Kelly Young Edited by Susan Sadoughi, MD, and André Sofair, MD, MPH Accidental ingestion of the atypical antipsychotic aripiprazole by two children was associated with false-positive results for amphetamine on urine drug screens, according to … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - November 2, 2015 Category: Primary Care Source Type: news

Safety of Vraylar vs. Other Antipsychotics Drugs Compared in New Drug...
Comparative safety research review covers Abilify (Bristol-Meyers), Fanapt (Novartis), INVEGA (J&J), Risperdal (J&J), Risperdal Consta (Janssen)(PRWeb October 26, 2015)Read the full story at http://www.prweb.com/releases/2015/10/prweb13042760.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - October 26, 2015 Category: Pharmaceuticals Source Type: news

Do We Need a New Pill Drill?
Commercials that get into our kids heads drive us crazy. When we see them salivating over enticing ads designed to make them pine for every last morsel of candy, new gimmick or any unhealthy vice, we are outraged. And we should be. It's pretty despicable companies do this. As adults, we are also of great interest to marketers, but the version of "candy" being shoved down our throats -- almost literally -- are prescription meds. The United States, along with New Zealand are the only two countries across the world that allows Direct-to-Consumer (DTC) pharmaceutical advertisements. We turn on our television and are bombar...
Source: Healthy Living - The Huffington Post - October 25, 2015 Category: Consumer Health News Source Type: news

Aristada™ (aripiprazole lauroxil) for the Treatment of Schizophrenia
Aristada™ (aripiprazole lauroxil), discovered and developed by Alkermes, is an antipsychotic drug indicated for the treatment of schizophrenia in adults. (Source: Drug Development Technology)
Source: Drug Development Technology - October 19, 2015 Category: Pharmaceuticals Source Type: news

Aristada (Aripiprazole Lauroxil Extended-release Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - October 14, 2015 Category: Drugs & Pharmacology Source Type: news

Extended-Release Schizophrenia Drug Approved (FREE)
By Kristin J. Kelley Edited by David G. Fairchild, MD, MPH, and Lorenzo Di Francesco, MD, FACP, FHM The FDA has approved extended-release aripiprazole lauroxil (marketed as … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - October 7, 2015 Category: Primary Care Source Type: news

FDA Clears Long-Lasting Drug for Schizophrenia
The FDA has approved a version of the antipsychotic drug aripiprazole that adults with schizophrenia can take every 4-6 weeks. WebMD has the details. (Source: WebMD Health)
Source: WebMD Health - October 6, 2015 Category: Consumer Health News Source Type: news

FDA Approves Alkermes' Injectable Schizophrenia Drug
Alkermes' Aristada (aripiprazole lauroxil) extended release injection is approved to treat adults with schizophrenia (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - October 6, 2015 Category: Pharmaceuticals Source Type: news

FDA Clears Long-Acting Aripiprazole for SchizophreniaFDA Clears Long-Acting Aripiprazole for Schizophrenia
The FDA has approved an injectable, long-acting version of Alkermes Inc's atypical antipsychotic aripiprazole to treat adults with schizophrenia. FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 6, 2015 Category: Consumer Health News Tags: Psychiatry News Alert Source Type: news

FDA approves new injectable drug to treat schizophrenia
On October 5, the U.S. Food and Drug Administration approved Aristada (aripiprazole lauroxil) extended release injection to treat adults with schizophrenia. Aristada is administered by a health care professional every four to six weeks using an injection in the arm or buttocks. (Source: Food and Drug Administration)
Source: Food and Drug Administration - October 6, 2015 Category: American Health Source Type: news

Alkermes' schizophrenia drug Aristada gets FDA nod
(Reuters) - The U.S. Food and Drug Administration on Monday approved Alkermes Plc's longer-acting injectable version of blockbuster schizophrenia pill Abilify, making the treatment available in two doses. (Source: Reuters: Health)
Source: Reuters: Health - October 5, 2015 Category: Consumer Health News Tags: healthNews Source Type: news

Alkermes's Aristada gets FDA approval to treat schizophrenia
Ireland-based Alkermes has received approval from the US Food and Drug Administration (FDA) for Aristada (aripiprazole lauroxil) extended-release injectable suspension to treat schizophrenia. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - October 5, 2015 Category: Pharmaceuticals Source Type: news